tetano
Editor, Senior Moderator
Curr Opin Virol
. 2021 Dec 30;53:101199.
doi: 10.1016/j.coviro.2021.12.015. Online ahead of print.
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
Rong Xiang[SUP] 1 [/SUP], Yang Wang[SUP] 1 [/SUP], Lili Wang[SUP] 2 [/SUP], Xiaoqian Deng[SUP] 1 [/SUP], Shanshan Huo[SUP] 3 [/SUP], Shibo Jiang[SUP] 4 [/SUP], Fei Yu[SUP] 5 [/SUP]
Affiliations
Abstract
The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.
. 2021 Dec 30;53:101199.
doi: 10.1016/j.coviro.2021.12.015. Online ahead of print.
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
Rong Xiang[SUP] 1 [/SUP], Yang Wang[SUP] 1 [/SUP], Lili Wang[SUP] 2 [/SUP], Xiaoqian Deng[SUP] 1 [/SUP], Shanshan Huo[SUP] 3 [/SUP], Shibo Jiang[SUP] 4 [/SUP], Fei Yu[SUP] 5 [/SUP]
Affiliations
- PMID: 35038651
- DOI: 10.1016/j.coviro.2021.12.015
Abstract
The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.